各题华肿瘤检测.pdf

益善 注：如果您收到的电子文摘无法正常显示或者您不愿接收本快讯，请回邮至market@ / lssue Dec. 2010年12月 LUX-Lung 1临床试验的新亚群分析结果表明：阿法替尼治疗EGFR突变肺癌患者效果明显 Medical News Today，2010/12/10 来自LUX-Lung 1 Ⅱb/Ⅲ期的临床试验研究结果表明，阿法替尼可明显延长EGFR突变患者的无进展生存期近4倍，突变患者的总生存期也存在延长趋势。 该试验的入组患者为接受化疗和第一代EGFR-TKIs （吉非替尼或厄洛替尼）治疗后疾病进展的晚期NSCLC患者，随机分为服用安慰剂的对照组以及服用阿法替尼的试 验组。分析数据来源于约2/3 的入组患者（391/585 ），这些患者很可能携有EGFR突变，判断标准为患者对EGFR-TKIs的药效反应及耐受情况。 上述试验结果是LUX-Lung 1临床试验的必威体育精装版研究结果，已在最近米兰召开的欧洲临床肿瘤内科学会（ESMO ）会议中汇报。 file:////E|/sanly工作/月刊/2010/12月刊/益善-zzx-12月刊-定稿V2.htm（第 1／15 页）2011-2-14 14:50:26 益善 阿法替尼是EGFR和HER2酪氨酸激酶的新型靶向口服抑制剂，主要用于实验性治疗实体肿瘤，例如NSCLC、乳腺癌以及头颈癌。 目前，LUX-Lung 3临床试验已开展，该临床试验是阿法替尼用于携有EGFR突变晚期NSCLC患者一线治疗的研究。 New Subgroup Analysis Of The LUX-Lung 1 Trial Suggests Benefit From Afatinib In Lung Cancer Patients Likely To Have EGFR Mutations Medical News Today，2010/12/10 New data to be presented show that afatinib (BIBW 2992) leads to a significant four-fold extension in progression-free survival, for lung cancer patients most likely to have an epidermal growth factor receptor (EGFR) mutation. In addition, this sub-group of patients showed a trend towards prolonged overall survival. The new updated post-hoc analysis for Boehringer Ingelheims investigational cancer compound afatinib comes from the phase IIb/III LUX-Lung 1 clinical trial. The LUX-Lung 1 trial compared afatinib to placebo in patients with advanced non-small cell lung cancer (NSCLC) whose disease progressed after receiving chemotherapy and a first-generation EGFR tyrosine kinase- inhibitor (TKI), gefitinib or erlotinib. The sub-group included in the analysis to be presented comprises two-thirds of all patients